• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Pacira BioSciences Inc.

    6/4/25 10:37:47 AM ET
    $PCRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001296965
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Pacira BioSciences, Inc.
    SEC File Number
    001-35060
    Address of Issuer
    2000 SIERRA POINT PARKWAY
    SUITE 900
    BRISBANE
    CALIFORNIA
    94005
    Phone
    650-242-8052
    Name of Person for Whose Account the Securities are To Be Sold
    WILLIAMS KRISTEN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    14376377226.244630466706/04/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/03/2025Restricted Stock VestingIssuerCheckbox not checked1437606/03/2025Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/04/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jared Cook, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Kristen M. Williams

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PCRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCRX

    DatePrice TargetRatingAnalyst
    1/30/2025$8.00 → $25.00Sell → Hold
    Truist
    8/13/2024$30.00 → $8.00Buy → Sell
    Truist
    8/12/2024$42.00 → $11.00Overweight → Neutral
    Piper Sandler
    8/12/2024$45.00 → $10.00Overweight → Underweight
    JP Morgan
    8/12/2024Outperform → Mkt Perform
    Raymond James
    8/12/2024$37.00 → $14.00Outperform → Sector Perform
    RBC Capital Mkts
    7/3/2024$38.00 → $25.00Overweight → Equal Weight
    Barclays
    3/7/2024$80.00 → $45.00Overweight
    JP Morgan
    More analyst ratings

    $PCRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      BRISBANE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced the granting of inducement awards on June 3, 2025 to 19 new employees under Pacira's Amended and Restated 2014 Inducement Plan (the "Inducement Plan") as a material inducement to each employee's entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the "Committee") without stockholder approval. 11 employees received stock options to purchase an a

      6/5/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

      -- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at the ASGCT Annual Meeting -- BRISBANE, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new preliminary data which suggests that clinical immunogenicity does not reduce sustained improvements in knee pain, stiffness and function provided by its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), following loc

      5/15/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

      BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: 2025 RBC Capital Markets Global Healthcare Conference on Wednesday, May 21st at 8:30AM ET.2025 Jefferies Global Healthcare Conference on Wednesday, June 4th at 8:45AM ET. Live audio of the virtual event can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks follo

      5/14/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Financials

    Live finance-specific insights

    See more
    • Pacira BioSciences Reports First Quarter 2025 Financial Results

      -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the first quarter of 2025. First Quarter 2025 Financial Highlights Total revenues of $168.9 millionNet product sales of $136.5 million for EXPAREL, $23.3 million for ZILRETTA, and $5.1 million for iovera°Net income of $4.8 million, or $0.10 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $44.1 million See "Non-GAAP Financial Informa

      5/8/25 4:00:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025

      BRISBANE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its first quarter financial results after the close of the U.S. markets on Thursday May 8, 2025. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the confer

      4/29/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results

      — Record revenues of $701 million in 2024 — — Full-year GAAP net loss of $100 million and adjusted EBITDA of $224 million — — Conference call today at 4:30 p.m. ET — PARSIPPANY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today reported financial results for the fourth quarter and full-year of 2024. "Pacira enters 2025 with a sharp focus on executing our 5x30 strategy to accelerate our transition into an innovative biopharmaceutical organization and therapeutic area leader in musculoskeletal pain and adjacencies," said Frank D. L

      2/27/25 4:05:00 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    SEC Filings

    See more
    • SEC Form 144 filed by Pacira BioSciences Inc.

      144 - Pacira BioSciences, Inc. (0001396814) (Subject)

      6/4/25 10:37:47 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Pacira BioSciences Inc.

      10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)

      5/8/25 4:07:07 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Pacira BioSciences, Inc. (0001396814) (Filer)

      5/8/25 4:06:04 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bigal Marcelo bought $20,034 worth of shares (1,512 units at $13.25), increasing direct ownership by 18% to 10,142 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/19/24 8:25:55 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Brege Laura bought $12,810 worth of shares (1,000 units at $12.81), increasing direct ownership by 6% to 17,552 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/19/24 8:25:46 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Yang Michael J. bought $25,800 worth of shares (2,000 units at $12.90), increasing direct ownership by 38% to 7,230 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      8/14/24 4:35:09 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pacira BioSciences upgraded by Truist with a new price target

      Truist upgraded Pacira BioSciences from Sell to Hold and set a new price target of $25.00 from $8.00 previously

      1/30/25 7:16:40 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences downgraded by Truist with a new price target

      Truist downgraded Pacira BioSciences from Buy to Sell and set a new price target of $8.00 from $30.00 previously

      8/13/24 7:53:59 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pacira BioSciences downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Pacira BioSciences from Overweight to Neutral and set a new price target of $11.00 from $42.00 previously

      8/12/24 8:01:11 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCRX
    Leadership Updates

    Live Leadership Updates

    See more
    • Pacira Announces Updates to Board of Directors

      -- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired from the Board. These changes align with Pacira's ongoing commitment to Board refreshment. With these changes, the Board is composed of nine directors, eight of whom are independent and

      1/30/25 8:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO

      Former CEO, Sander van Deventer to become President of R&D Lead program VTx-002 for Amyotrophic Lateral Sclerosis (ALS) advances into IND-enabling studies following favorable FDA feedback of pre-clinical package Expansion of corporate footprint into the US (Boston) VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces the appointment of Jim Scibetta as Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241216441837/en/VectorY strengthens Leadership Team with appointment of Jim Scibetta as new CEO (Photo

      12/16/24 7:00:00 AM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

      enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of

      5/15/24 4:05:00 PM ET
      $ENGN
      $NAMS
      $NKTX
      $PCRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $PCRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PCRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Senior Vice President, Finance Riker Lauren sold $146,208 worth of shares (5,578 units at $26.21) and covered exercise/tax liability with 3,374 shares, decreasing direct ownership by 13% to 59,564 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      6/5/25 5:40:22 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Administrative Officer Williams Kristen covered exercise/tax liability with 6,162 shares and sold $377,226 worth of shares (14,376 units at $26.24), decreasing direct ownership by 11% to 161,574 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      6/5/25 5:37:51 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Slonin Jonathan covered exercise/tax liability with 5,084 shares, decreasing direct ownership by 3% to 181,960 units (SEC Form 4)

      4 - Pacira BioSciences, Inc. (0001396814) (Issuer)

      6/5/25 5:37:39 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      1/19/24 2:40:54 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      2/14/23 1:31:32 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Pacira BioSciences Inc. (Amendment)

      SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)

      1/23/23 3:52:35 PM ET
      $PCRX
      Biotechnology: Pharmaceutical Preparations
      Health Care